Logo
x

Search

Subscribe Now

Amyotrophic Lateral Sclerosis

Disease of the Month - Amyotrophic Lateral Sclerosis (ALS)

Disease of the Month - Amyotrophic Lateral Sclerosis (ALS)

  • May 11, 2023
Denali Presented Results of DNL343 and SAR443820 in P-I Clinical Studies for the Treatment of Amyotrophic Lateral Sclerosis at NEALS 2021

Denali Presented Results of DNL343 and SAR443820 in P-I Clinical Studies for the Treatment of Amyotrophic Lateral Sclerosis at NEA...

  • October 7, 2021
Alexion to Discontinue its P-III CHAMPION-ALS Trial of Ultomiris (ravulizumab) for Amyotrophic Lateral Sclerosis

Alexion to Discontinue its P-III CHAMPION-ALS Trial of Ultomiris (ravulizumab) for Amyotrophic Lateral Sclerosis

  • August 23, 2021
Seelos' SLS-005 (Trehalose) Receives EC's Orphan Drug Designation to Treat Amyotrophic Lateral Sclerosis

Seelos' SLS-005 (Trehalose) Receives EC's Orphan Drug Designation to Treat Amyotrophic Lateral Sclerosis

  • May 28, 2021
MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US

MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US

  • January 22, 2021
Project ALS' Prosetin Receives the US FDA's Orphan Drug Designation for Amyotrophic Lateral Sclerosis

Project ALS' Prosetin Receives the US FDA's Orphan Drug Designation for Amyotrophic Lateral Sclerosis

  • September 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.